Previous 10 | Next 10 |
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testi...
2023-05-12 16:28:43 ET Interpace Biosciences press release ( OTCQX:IDXG ): Q1 GAAP EPS of $0.10. Revenue of $9.8M (-5.6% Y/Y). For further details see: Interpace Biosciences GAAP EPS of $0.10, revenue of $9.8M
PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net ...
2023-03-27 17:18:33 ET Interpace Biosciences press release ( OTCQX:IDXG ): Q4 GAAP EPS of -$0.33. Revenue of $8.33M (-8.6% Y/Y). For further details see: Interpace Biosciences GAAP EPS of -$0.33, revenue of $8.33M
PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2022 and provided a business and financial update. ...
Interpace Biosciences press release ( OTCQX:IDXG ): Q3 GAAP EPS of $3.35. Revenue of $8.2M Gross Profit percentage was 58% compared to 55% for the prior year quarter, an improvement year over year. Loss from Continuing Operations was approximately$(1.3) million in both...
Q3 Revenue of $ 8.2 million up 2 % versus Prior Year Q3 Adjusted EBITDA Positive Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ...
Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved ...
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...